Xiaopei Shen
Xiaopei Shen
Fujian Medical University
Bestätigte E-Mail-Adresse bei
Zitiert von
Zitiert von
Differential Clinicopathological Risk and Prognosis of Major Papillary Thyroid Cancer Variants
X Shi, R Liu, F Basolo, R Giannini, X Shen, D Teng, H Guan, Z Shan, ...
The Journal of Clinical Endocrinology & Metabolism 101 (1), 264-274, 2016
Separate enrichment analysis of pathways for up-and downregulated genes
G Hong, W Zhang, H Li, X Shen, Z Guo
Journal of the Royal Society Interface 11 (92), 20130950, 2014
Patient Age–Associated Mortality Risk Is Differentiated by BRAF V600E Status in Papillary Thyroid Cancer
X Shen, G Zhu, R Liu, D Viola, R Elisei, E Puxeddu, L Fugazzola, ...
Journal of Clinical Oncology 36 (5), 438-445, 2018
The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer
F Wang, X Yu, X Shen, G Zhu, Y Huang, R Liu, D Viola, R Elisei, ...
The Journal of Clinical Endocrinology & Metabolism 102 (9), 3241–3250, 2017
BRAF V600E mutation-assisted risk stratification of solitary intrathyroidal papillary thyroid cancer for precision treatment
Y Huang, S Qu, G Zhu, F Wang, R Liu, X Shen, D Viola, R Elisei, ...
JNCI: Journal of the National Cancer Institute 110 (4), 362-370, 2018
A six-genotype genetic prognostic model for papillary thyroid cancer
X Shen, R Liu, M Xing
Endocrine-related cancer, ERC-16-0402, 2017
REC8 is a novel tumor suppressor gene epigenetically robustly targeted by the PI3K pathway in thyroid cancer
D Liu, X Shen, G Zhu, M Xing
Oncotarget 6 (36), 39211, 2015
T Zhang, X Shen, M Xing
Journal of the National Cancer Institute 108 (8), 2016
The genetic duet of BRAF V600E and TERT promoter mutations robustly predicts loss of radioiodine avidity in recurrent papillary thyroid cancer
J Liu, R Liu, X Shen, G Zhu, B Li, M Xing
Journal of Nuclear Medicine 61 (2), 177-182, 2020
BRAF V600E confers male sex disease-specific mortality risk in patients with papillary thyroid cancer
F Wang, S Zhao, X Shen, G Zhu, R Liu, D Viola, R Elisei, E Puxeddu, ...
Journal of clinical oncology 36 (27), 2787, 2018
BRAF V600E status may facilitate decision-making on active surveillance of low-risk papillary thyroid microcarcinoma
KJ Kim, SG Kim, J Tan, X Shen, D Viola, R Elisei, E Puxeddu, L Fugazzola, ...
European Journal of Cancer 124, 161-169, 2020
Distinct functional patterns of gene promoter hypomethylation and hypermethylation in cancer genomes
X Shen, Z He, H Li, C Yao, Y Zhang, L He, S Li, J Huang, Z Guo
Public Library of Science 7 (9), e44822, 2012
Reproducibility and concordance of differential DNA methylation and gene expression in cancer
C Yao, H Li, X Shen, Z He, L He, Z Guo
PLoS One 7 (1), e29686, 2012
An integrated approach to uncover driver genes in breast cancer methylation genomes
X Shen, S Li, L Zhang, H Li, G Hong, XX Zhou, T Zheng, W Zhang, C Hao, ...
PLoS One 8 (4), e61214, 2013
BRAF V600E Status Sharply Differentiates Lymph Node Metastasis-associated Mortality Risk in Papillary Thyroid Cancer
Y Tao, F Wang, X Shen, G Zhu, R Liu, D Viola, R Elisei, E Puxeddu, ...
The Journal of Clinical Endocrinology & Metabolism 106 (11), 3228-3238, 2021
Rank-based predictors for response and prognosis of neoadjuvant taxane-anthracycline-based chemotherapy in breast cancer
L Zhang, C Hao, X Shen, G Hong, H Li, X Zhou, CY Liu, Z Guo
Breast cancer research and treatment 139 (2), 361-369, 2013
Epigenetically upregulated WIPF1 plays a major role in BRAF V600E-promoted papillary thyroid cancer aggressiveness
T Zhang, X Shen, R Liu, G Zhu, J Bishop, M Xing
Oncotarget 8 (1), 900, 2017
Therapeutic targeting of FOS in mutant TERT cancers through removing TERT suppression of apoptosis via regulating survivin and TRAIL-R2
R Liu, J Tan, X Shen, K Jiang, C Wang, G Zhu, M Xing
Proceedings of the National Academy of Sciences 118 (11), 2021
Finding co-mutated genes and candidate cancer genes in cancer genomes by stratified false discovery rate control
J Wang, Y Zhang, X Shen, J Zhu, L Zhang, J Zou, Z Guo
Molecular BioSystems 7 (4), 1158-1166, 2011
Genes dysregulated to different extent or oppositely in estrogen receptor-positive and estrogen receptor-negative breast cancers
X Zhou, T Shi, B Li, Y Zhang, X Shen, H Li, G Hong, C Liu, Z Guo
PLoS One 8 (7), e70017, 2013
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20